Abstract
Guidelines for antithrombotic therapy are complex, especially if a patient has several indications that require antithrombotic therapy. In general, no patient should receive lifelong double or triple antithrombotic therapy. In this overview, we outline the most common indications for mono, double and triple antithrombotic therapy; the preferred antithrombotic therapy and the recommended duration of therapy. Both antiplatelet therapy and therapeutic anticoagulation therapy with vitamin K antagonists or direct oral anticoagulants were included. European guidelines were used or, if no European guidelines were available, the Dutch guidelines were used.
| Original language | English |
|---|---|
| Pages (from-to) | 730-737 |
| Number of pages | 8 |
| Journal | Postgraduate medical journal |
| Volume | 97 |
| Issue number | 1153 |
| DOIs | |
| Publication status | Published - Nov 2021 |
| Externally published | Yes |
Keywords
- Anticoagulants/administration & dosage
- Atrial Fibrillation/complications
- Coronary Artery Disease/complications
- Fibrinolytic Agents/administration & dosage
- Humans
- Practice Guidelines as Topic
- Thromboembolism/prevention & control
- Vitamin K/antagonists & inhibitors
Fingerprint
Dive into the research topics of 'Guidelines for mono, double and triple antithrombotic therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver